Compare CDP & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | VERA |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.4B |
| IPO Year | N/A | 2021 |
| Metric | CDP | VERA |
|---|---|---|
| Price | $32.45 | $43.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $33.00 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | ★ 10.15 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $763,923,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.21 | N/A |
| P/E Ratio | $23.68 | ★ N/A |
| Revenue Growth | ★ 1.36 | N/A |
| 52 Week Low | $23.92 | $18.53 |
| 52 Week High | $32.14 | $56.05 |
| Indicator | CDP | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 72.65 | 42.76 |
| Support Level | $30.93 | $40.87 |
| Resistance Level | $30.75 | $45.51 |
| Average True Range (ATR) | 0.63 | 2.18 |
| MACD | 0.16 | -0.67 |
| Stochastic Oscillator | 83.39 | 22.10 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.